Some Ozempic (semaglutide) side effects can make the medication hard to tolerate — learn everything you need to know about the injection here.
References
American Thyroid Association. (n.d.). Cancer of the thyroid.
American Thyroid Association. (n.d.). Medullary thyroid cancer.
Collins, L., et al. (2022). Glucagon-like peptide-1 receptor agonists. StatPearls.
Kawanami, D., et al. (2020). GLP-1 receptor agonists in diabetic kidney disease: From clinical outcomes to mechanisms. Frontiers in Pharmacology.
Liu, Y., et al. (2019). Risk of malignant neoplasia with glucagon-Like peptide-1 receptor agonist treatment in patients with type 2 diabetes: A meta-analysis. Journal of Diabetes Research.
National Cancer Institute. (n.d.). Multiple endocrine neoplasia type 2 syndrome.
National Institute of Diabetes and Digestive and Kidney Diseases. (2017). Treatment for gallstones.
National Kidney Foundation. (n.d.). Acute kidney injury.
Novo Nordisk. (2021). Wegovy [package insert].
Shomali, M. (2014). Optimizing the care of patients with type 2 diabetes using incretin-based therapy: Focus on GLP-1 receptor agonists. Clinical Diabetes.
Smits, M. M., et al. (2021). Safety of semaglutide. Frontiers in Endocrinology.
Wilding, J. P. H., et al. (2021). Once-weekly Semaglutide in adults with overweight or obesity. The New England Journal of Medicine.
Why trust our experts?
Search and compare options
